Cargando…
Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data
BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) results in kidney cyst development and enlargement, resulting in chronic kidney disease (CKD) leading to renal failure. This study sought to determine if ADPKD patients in the early stages of CKD contribute to a sizable economic burden...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345925/ https://www.ncbi.nlm.nih.gov/pubmed/25759590 http://dx.doi.org/10.2147/CEOR.S75523 |
_version_ | 1782359655792508928 |
---|---|
author | Knight, Tyler Schaefer, Caroline Krasa, Holly Oberdhan, Dorothee Chapman, Arlene Perrone, Ronald D |
author_facet | Knight, Tyler Schaefer, Caroline Krasa, Holly Oberdhan, Dorothee Chapman, Arlene Perrone, Ronald D |
author_sort | Knight, Tyler |
collection | PubMed |
description | BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) results in kidney cyst development and enlargement, resulting in chronic kidney disease (CKD) leading to renal failure. This study sought to determine if ADPKD patients in the early stages of CKD contribute to a sizable economic burden for the US health care system. METHODS: This was a retrospective, matched cohort study, reviewing medical resource utilization (MRU) and costs for adults in a US private-payer claims database with a diagnosis code of ADPKD (ICD-9-CM 753.13). ADPKD patients were matched by age grouping (0–17, 18–34, 35–44, 45–54, 55–64, and 65+ years) and sex to controls to understand the burden of ADPKD. Descriptive statistics on 6-month MRU and costs were assessed by CKD stages, dialysis use, or previous renal transplant. RESULTS: The analysis included ADPKD patients in CKD stages 1–5 (n=316 to n=860), dialysis (n=586), and post-transplant (n=615). Mean ages did not differ across CKD stages (range 43–56 years). Men were the majority in the later stages but the minority in the early stages. The proportion of patients with at least one hospitalization increased with CKD stage, (12% to >40% CKD stage 2 to stage 5, dialysis or post-transplant). The majority had at least one hospital outpatient visit and at least one pharmacy claim. Total 6-month per-patient costs were greater among ADPKD patients than in age-matched and sex-matched healthy non-ADPKD controls (P<0.001 for all comparisons). CONCLUSION: ADPKD patients with normal kidney function are associated with a significant economic burden to the health care system relative to the general population. Any treatments that delay progression to later stages of CKD may provide potential health care cost offsets. |
format | Online Article Text |
id | pubmed-4345925 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-43459252015-03-10 Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data Knight, Tyler Schaefer, Caroline Krasa, Holly Oberdhan, Dorothee Chapman, Arlene Perrone, Ronald D Clinicoecon Outcomes Res Original Research BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) results in kidney cyst development and enlargement, resulting in chronic kidney disease (CKD) leading to renal failure. This study sought to determine if ADPKD patients in the early stages of CKD contribute to a sizable economic burden for the US health care system. METHODS: This was a retrospective, matched cohort study, reviewing medical resource utilization (MRU) and costs for adults in a US private-payer claims database with a diagnosis code of ADPKD (ICD-9-CM 753.13). ADPKD patients were matched by age grouping (0–17, 18–34, 35–44, 45–54, 55–64, and 65+ years) and sex to controls to understand the burden of ADPKD. Descriptive statistics on 6-month MRU and costs were assessed by CKD stages, dialysis use, or previous renal transplant. RESULTS: The analysis included ADPKD patients in CKD stages 1–5 (n=316 to n=860), dialysis (n=586), and post-transplant (n=615). Mean ages did not differ across CKD stages (range 43–56 years). Men were the majority in the later stages but the minority in the early stages. The proportion of patients with at least one hospitalization increased with CKD stage, (12% to >40% CKD stage 2 to stage 5, dialysis or post-transplant). The majority had at least one hospital outpatient visit and at least one pharmacy claim. Total 6-month per-patient costs were greater among ADPKD patients than in age-matched and sex-matched healthy non-ADPKD controls (P<0.001 for all comparisons). CONCLUSION: ADPKD patients with normal kidney function are associated with a significant economic burden to the health care system relative to the general population. Any treatments that delay progression to later stages of CKD may provide potential health care cost offsets. Dove Medical Press 2015-02-20 /pmc/articles/PMC4345925/ /pubmed/25759590 http://dx.doi.org/10.2147/CEOR.S75523 Text en © 2015 Knight et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Knight, Tyler Schaefer, Caroline Krasa, Holly Oberdhan, Dorothee Chapman, Arlene Perrone, Ronald D Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data |
title | Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data |
title_full | Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data |
title_fullStr | Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data |
title_full_unstemmed | Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data |
title_short | Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data |
title_sort | medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the usa: a retrospective matched cohort analysis of private insurer data |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345925/ https://www.ncbi.nlm.nih.gov/pubmed/25759590 http://dx.doi.org/10.2147/CEOR.S75523 |
work_keys_str_mv | AT knighttyler medicalresourceutilizationandcostsassociatedwithautosomaldominantpolycystickidneydiseaseintheusaaretrospectivematchedcohortanalysisofprivateinsurerdata AT schaefercaroline medicalresourceutilizationandcostsassociatedwithautosomaldominantpolycystickidneydiseaseintheusaaretrospectivematchedcohortanalysisofprivateinsurerdata AT krasaholly medicalresourceutilizationandcostsassociatedwithautosomaldominantpolycystickidneydiseaseintheusaaretrospectivematchedcohortanalysisofprivateinsurerdata AT oberdhandorothee medicalresourceutilizationandcostsassociatedwithautosomaldominantpolycystickidneydiseaseintheusaaretrospectivematchedcohortanalysisofprivateinsurerdata AT chapmanarlene medicalresourceutilizationandcostsassociatedwithautosomaldominantpolycystickidneydiseaseintheusaaretrospectivematchedcohortanalysisofprivateinsurerdata AT perroneronaldd medicalresourceutilizationandcostsassociatedwithautosomaldominantpolycystickidneydiseaseintheusaaretrospectivematchedcohortanalysisofprivateinsurerdata |